Erlotinib, erlotinib-sulindac versus placebo: A randomized, double-blind, placebo-controlled window trial in operable head and neck cancer

Neil D. Gross, Julie E. Bauman, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang, Simion Chiosea, Brian L. Hood, Melanie S. Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Seungwon Kim, Athanassios Argiris, Lori Wirth, Marina N. Nikiforova, Jill M. Siegfried, Jennifer R. Grandis

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'Erlotinib, erlotinib-sulindac versus placebo: A randomized, double-blind, placebo-controlled window trial in operable head and neck cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences